Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer

International Journal of Radiation Oncology Biology Physics

Volumn 48, Issue 2, 2000, Pages 393-397

  Bellon, Jennifer R ^a   Lindsley, Karen L ^a   Ellis, Georgiana K ^a   Gralow, Julie R ^a   Livingston, Robert B ^a   Austin Seymour, Mary M ^a,b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b Box 356043 ^*  (United States)

Author keywords

Breast; Docetaxel; Paclitaxel; Radiation

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; NAVELBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIBROSIS; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MULTIMODALITY CANCER THERAPY; PERICARDITIS; PRIORITY JOURNAL; RADIATION DOSE; RADIATION HAZARD; SKIN TOXICITY; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 0033828059     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)00636-2     Document Type: Article

References (36)

1. Gandara D.R., Edelman M.J., Lau D. Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer. Semin Oncol. 26:1999;3-7.
2. Herscher L.L., Cook J. Taxanes as radiosensitizers for head and neck cancer. Curr Opin Oncol. 11:1999;183-186.
3. Seidman A.D. The emerging role of paclitaxel in breast cancer therapy. Clin Cancer Res. 1:1995;247-256.
4. Colevas A.D., Posner M.R. Docetaxel in head and neck cancer A review . Am J Clin Oncol. 21:1998;482-486.
5. Hortobagyi G. An expanding role for docetaxel. Semin Oncol. 25:1998;1-3.
6. Henderson IC, Berry D, Demetri G; et al. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proceedings of the American Society of Clinical Oncology. Vol. 17. 1998 (abstract 390A).
7. Mason K.A., Hunter N.R., Milas M., et al. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res. 3:1997;2431-2438.
8. Zanelli G.D., Quaia M., Robieux I., et al. Paclitaxel as a radiosensitiser A proposed schedule of administration based on in vitro data and pharmacokinetic calculations . Eur J Cancer. 33:1997;486-492.
9. Buchholz T.A., Austin-Seymour M.M., Moe R.E., et al. Effect of delay in radiation in the combined modality treatment of breast cancer. Int J Radiat Oncol Biol Phys. 26:1993;23-35.
10. Recht A., Come S.E., Henderson I.C., et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med. 334:1996;1356-1361.
11. Johnson R, Bhattacharyya G. Statistics: Principles and methods. New York: John Wiley; 1985, p. 304-308, 465-487.
12. Dowell J.E., Sinard R., Yardley D.A., et al. Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers. Semin Radiat Oncol. 9:1999;97-101.
13. Rathmann J., Leopold K.A., Rigas J.R. Daily paclitaxel and thoracic radiation therapy for non-small cell lung cancer Preliminary results . Semin Radiat Oncol. 9:1999;130-135.
14. Ettinger D.S. Concurrent paclitaxel-containing regimens and thoracic radiation therapy for limited-disease small cell lung cancer. Semin Radiat Oncol. 9:1999;148-150.
15. Glantz M., Choy H., Kearns C., et al. Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors Preliminary results and promising directions . Semin Oncol. 25:1995;26-32.
16. Ornstein D.L., Rigas J.R. Taxotere Clinical trials in non-small cell lung cancer . Oncologist. 3:1998;86-93.
17. Mauer A.M., Masters G.A., Haraf D.J., et al. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol. 16:1998;159-164.
18. Varveris H., Delakas D., Anezinis P., et al. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma A preliminary report of tolerance and local control . Anticancer Res. 17:1997;4771-4780.
19. Formenti S.C., Symmans W.F., Volm M., et al. Concurrent paclitaxel and radiation therapy for breast cancer. Semin Radiat Oncol. 9:(2 suppl. 1):1999;34-42.
20. Tishler R.B., Schiff P.B., Geard C.R., et al. Taxol A novel radiation sensitizer . Int J Radiat Oncol Biol Phys. 22:1992;613-617.
21. Liebmann J., Cook J.A., Fisher J., et al. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst. 86:1994;441-446.
22. Tishler R.B., Geard C.R., Hall E.J., et al. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res. 52:1992;3495-3497.
23. Choy H., Rodriguez F.F., Koester S., et al. Investigation of taxol as a potential radiation sensitizer. Cancer. 71:1993;3773-3778.
24. Talwar N., Redpath J.L. Schedule dependence of the interaction of radiation and Taxol in Hela cells. Radiat Res. 148:1997;48-53.
25. Gangemi R.M., Tiso M., Marchetti C., et al. Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death. Cancer Chemother Pharmacol. 36:1995;385-392.
26. Milas L., Hunter N.R., Kurdoglu B., et al. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with Taxol. Cancer Chemother Pharmacol. 35:1995;297-303.
27. Milross C.G., Mason K.A., Hunter N.R., et al. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst. 88:1996;1308-1314.
28. Ringel I., Horwitz S.B. Studies with RP 56976 (taxotere) A semisynthetic analogue of taxol . J Natl Cancer Inst. 83:1991;288-291.
29. Riou J.F., Naudin A., Lavelle F. Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun. 187:1992;164-170.
30. Hennequin C., Giocanti N., Favaudon V. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer. 71:1995;1194-1198.
31. Milas L., Hunter N.R., Mason K.A., et al. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res. 55:1995;3564-3568.
32. Vujovic O., Perera F., Dar A.R., et al. Does delay in breast irradiation following conservative breast surgery in node-negative breast cancer have an impact on risk of recurrence. Int J Radiat Oncol Biol Phys. 40:1998;869-874.
33. Meek A.G., Park T.L., Weiss T.A., et al. Effect of delayed radiation therapy on local control in breast conservation therapy. Radiology. 200:1996;615-619.
34. Perez C.A., Grigsby P.W., Castro-Vita H., et al. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 32:1995;1275-1288.
35. Fowler J.F., Lindstrom M.J. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys. 23:1992;457-467.
36. Eifel P.J., Thames H.D. Has the influence of treatment duration on local control of carcinoma of the cervix been defined? Int J Radiat Oncol Biol Phys. 32:1995;1527-1529.